U.S Therapeutic Plasma Exchange Market Size To Hit USD 383.07 MN By 2032
The U.S therapeutic plasma exchange market size was estimated at USD 206 million in 2022 and is expected to hit around USD 383.07 million by 2032, poised to reach at a notable CAGR of 6.4% during the forecast period 2023 to 2032.
Key Takeaways:
Growth in this market is driven by the rising prevalence of chronic diseases and technological advancements. However, factors such as the high cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model are expected to restrain the growth of this market to a certain extent during the forecast period.
U.S Therapeutic Plasma Exchange Market Report Scope
| Report Attribute | Details |
| Market Size in 2023 | USD 219.18 Million |
| Market Size by 2032 | USD 383.07 Million |
| Growth Rate From 2023 to 2032 | CAGR of 6.4% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Product & Technology, Indication, End User |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Miltenyi Biotec (Germany), Medica S.p.A. (Italy), Medicap Clinic GmbH (Germany), and Infomed (Switzerland). |
US Therapeutic Plasma Exchange Market Dynamics
Driver: Technological advancement
Continuous-flow centrifugation technology is a high-precision approach that has been refined over the past decade. It brings innovations in patient comfort and more efficient processing of blood and plasma products. This technique requires minimal blood flow compared with other technologies, such as membrane separation approaches. It is an improved technology that allows easy access to blood through the patient’s peripheral veins (antecubital or brachial), as compared with other membrane-based apheresis devices that mostly require invasive central venous catheterization. These technical innovations also result in better patient comfort and safety during the TPE procedure (than was previously possible) and more accurate fluid balance control for better hemodynamic stability during treatment.
Restraint: High cost of devices
The cost of apheresis devices is a critical factor in determining the adoption of plasma exchange by healthcare providers and, ultimately, by patients. Apheresis devices are used by blood banks for blood component collection, while hospitals use these devices for therapeutic plasma exchange procedures. The high cost of apheresis devices and disposables also increases the overall cost of apheresis procedures. For instance, in the US, the cost of an apheresis procedure is ~USD 2,500 per treatment. Patients might not opt for these procedures owing to their high cost.
Opportunity: Therapeutic plasma exchange for pediatric patients
The growing adoption of therapeutic plasma exchange for the treatment of various diseases is expected to offer potential growth opportunities to market players in the coming years. Therapeutic plasma exchange (TPE) is used in the treatment of neurological, hematological, renal, and autoimmune diseases with known or suspected immune pathogenesis. The use of therapeutic plasma exchange procedures in pediatric patients is very low. This therapeutic modality presents several technical challenges in children but is increasingly being used in pediatric nephrology. Owing to advances in technology, TPE procedures are carried out in pediatric patients for renal diseases.
Challenge: Dearth of skilled professionals
Therapeutic plasma exchange procedures require skilled professionals and apheresis nurse specialists, as most of these procedures are performed using apheresis systems. However, globally, there is a shortage of these physicians and surgeons. As the demand for TPA has increased, so has the need for apheresis nurses with their expertise in clinical patient care, transfusion medicine, and technology. Apheresis nurses provide care to a diversified population ranging from healthy donors to acute or chronically ill patients while adhering to strict, ever-changing regulatory issues. During an apheresis procedure, the nurse manages the donor/patient’s clinical status, the venous access, the infusion of blood components or specialized fluids, and the apheresis device. Additional responsibilities include donor/patient/family/public education.
Recent Developments
Some of the prominent players in the U.S Therapeutic Plasma Exchange Market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the U.S Therapeutic Plasma Exchange market.
US Therapeutic Plasma Exchange Market, By Product & Technology
US Therapeutic Plasma Exchange Market, By Indication
US Therapeutic Plasma Exchange Market, By End User
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers